Quick Answer
Axsome Therapeutics, Inc. reported Net Income Loss of -$183.17 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed an increase of +36.2% in Net Income Loss from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: -$5.87 million | Q2 2016: -$6.81 million | Q3 2016: -$7.19 million | Q4 2016: -$7.33 million | Q1 2017: -$8.00 million | Q2 2017: -$7.08 million | Q3 2017: -$6.43 million | Q4 2017: -$7.43 million | Q1 2018: -$4.81 million | Q2 2018: -$8.28 million | Q3 2018: -$8.28 million | Q4 2018: -$9.60 million | Q1 2019: -$10.64 million | Q2 2019: -$13.76 million | Q3 2019: -$19.14 million | Q4 2019: -$24.81 million | Q1 2020: -$32.48 million | Q2 2020: -$18.33 million | Q3 2020: -$22.92 million | Q4 2020: -$29.16 million | Q1 2021: -$29.26 million | Q2 2021: -$32.28 million | Q3 2021: -$34.88 million | Q1 2022: -$39.63 million | Q2 2022: -$41.44 million | Q3 2022: -$44.82 million | Q1 2023: -$11.22 million | Q2 2023: -$67.17 million | Q3 2023: -$62.20 million | Q1 2024: -$68.36 million | Q2 2024: -$79.35 million | Q3 2024: -$64.60 million | Q1 2025: -$59.41 million | Q2 2025: -$47.97 million | Q3 2025: -$47.23 million.
- Over the full 12 years of available data (2014 to 2025), Axsome Therapeutics, Inc.'s Net Income Loss has declined by 2,952.6%.
- Historical annual values: Fiscal year 2025: -$183.17 million | Fiscal year 2024: -$287.22 million | Fiscal year 2023: -$239.24 million | Fiscal year 2022: -$187.13 million | Fiscal year 2021: -$130.40 million | Fiscal year 2020: -$102.90 million | Fiscal year 2019: -$68.35 million | Fiscal year 2018: -$30.97 million | Fiscal year 2017: -$28.94 million | Fiscal year 2016: -$27.20 million | Fiscal year 2015: -$12.21 million | Fiscal year 2014: -$6.00 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: